Tag: Zanamivir

When administered early in the course of illness, neuraminidase inhibitors can significantly reduce the duration and severity of influenza symptoms. This class of antiviral medications specifically targets and inhibits the neuraminidase protein found on the surface of influenza viruses, effectively stopping the infection from spreading within the body.

First approved for public use in 1999, zanamivir (Relenza) was the first commercially available neuraminidase inhibitor specifically designed for the treatment and prevention of influenza. This antiviral medication targets a specific enzyme on the surface of the influenza virus to stop its spread. Understanding what is the mechanism of action of zanamivir relenza reveals how this targeted therapy provides a powerful defense against influenza A and B.